BACKGROUND: Alterations of the short arm of chromosome 12 (12p) occur in various hematologic malignancies and ETV6 and CDKN1B, which are located on 12p, have been implicated as leukemogenic genes of interest. DESIGN AND METHODS: We selected seven patients with myeloid malignancies and small 12p deletions detected by fluorescence in situ hybridization encompassing only the region centromeric of ETV6 and further evaluated them by single nucleotide polymorphism microarrays. RESULTS: The minimally deleted region contained only nine genes. These genes were subsequently analyzed by microarray expression profiling in an independent cohort of 781 patients, most, but not all, of whom had different hematologic malignancies CREBL2, MANSC1, and CDKN1B were expressed in more than 25% of cases, while the other six genes were expressed in only a minority of cases. As CDKN1B is a cell cycle regulator and functions as a tumor suppressor gene, this gene was selected for further expression studies in 286 patients with acute myeloid leukemia. When comparing patients with low CDKN1B expression (expression level<1,160; 1st quartile) with those with intermediate or high expression (2nd-4th quartiles), certain mutations were observed more frequently in the former: RUNX1-RUNX1T1 (11/83, 13.3% versus 5/203; 2.5%; P=0.001), PML-RARA rearrangements (11/83, 13.3% versus 4/203, 2.0%; P<0.001), 11q23/MLL rearrangements (6/83, 7.2% versus 4/203, 2.0%; P=0.038), and FLT3-TKD mutations (7/63, 11.1% versus 6/167, 3.6%; P=0.047). The median overall survival of patients with low CDKN1B expression was longer than that of patients with intermediate/high expression (not reached versus 14.9 months; P=0.005). Likewise, patients with low CDKN1B expression had a longer event-free survival than those with intermediate/high expression (31.0 versus 9.7 months; P=0.013). CONCLUSIONS: CDKN1B is an interesting candidate gene as a potential biomarker for prognostication in acute myeloid leukemia.
BACKGROUND: Alterations of the short arm of chromosome 12 (12p) occur in various hematologic malignancies and ETV6 and CDKN1B, which are located on 12p, have been implicated as leukemogenic genes of interest. DESIGN AND METHODS: We selected seven patients with myeloid malignancies and small 12p deletions detected by fluorescence in situ hybridization encompassing only the region centromeric of ETV6 and further evaluated them by single nucleotide polymorphism microarrays. RESULTS: The minimally deleted region contained only nine genes. These genes were subsequently analyzed by microarray expression profiling in an independent cohort of 781 patients, most, but not all, of whom had different hematologic malignanciesCREBL2, MANSC1, and CDKN1B were expressed in more than 25% of cases, while the other six genes were expressed in only a minority of cases. As CDKN1B is a cell cycle regulator and functions as a tumor suppressor gene, this gene was selected for further expression studies in 286 patients with acute myeloid leukemia. When comparing patients with low CDKN1B expression (expression level<1,160; 1st quartile) with those with intermediate or high expression (2nd-4th quartiles), certain mutations were observed more frequently in the former: RUNX1-RUNX1T1 (11/83, 13.3% versus 5/203; 2.5%; P=0.001), PML-RARA rearrangements (11/83, 13.3% versus 4/203, 2.0%; P<0.001), 11q23/MLL rearrangements (6/83, 7.2% versus 4/203, 2.0%; P=0.038), and FLT3-TKD mutations (7/63, 11.1% versus 6/167, 3.6%; P=0.047). The median overall survival of patients with low CDKN1B expression was longer than that of patients with intermediate/high expression (not reached versus 14.9 months; P=0.005). Likewise, patients with low CDKN1B expression had a longer event-free survival than those with intermediate/high expression (31.0 versus 9.7 months; P=0.013). CONCLUSIONS:CDKN1B is an interesting candidate gene as a potential biomarker for prognostication in acute myeloid leukemia.
Authors: F P G Silva; B Morolli; C T Storlazzi; A Zagaria; L Impera; B Klein; H Vrieling; H C Kluin-Nelemans; M Giphart-Gassler Journal: Leukemia Date: 2008-02-28 Impact factor: 11.528
Authors: Claudia D Baldus; Christian Thiede; Silke Soucek; Clara D Bloomfield; Eckhard Thiel; Gerhard Ehninger Journal: J Clin Oncol Date: 2006-01-17 Impact factor: 44.544
Authors: Manu Gupta; Manoj Raghavan; Rosemary E Gale; Claude Chelala; Christopher Allen; Gael Molloy; Tracy Chaplin; David C Linch; Jean-Baptiste Cazier; Bryan D Young Journal: Genes Chromosomes Cancer Date: 2008-09 Impact factor: 5.006
Authors: Alexander Kohlmann; Thomas J Kipps; Laura Z Rassenti; James R Downing; Sheila A Shurtleff; Ken I Mills; Amanda F Gilkes; Wolf-Karsten Hofmann; Giuseppe Basso; Marta Campo Dell'orto; Robin Foà; Sabina Chiaretti; John De Vos; Sonja Rauhut; Peter R Papenhausen; Jesus M Hernández; Eva Lumbreras; Allen E Yeoh; Evelyn S Koay; Rachel Li; Wei-Min Liu; Paul M Williams; Lothar Wieczorek; Torsten Haferlach Journal: Br J Haematol Date: 2008-09 Impact factor: 6.998
Authors: N G Bediaga; J M Aznar; X Elcoroaristizabal; O Albóniga; F Gómez-Busto; I Artaza Artabe; Ana Rocandio; M M de Pancorbo Journal: Age (Dordr) Date: 2015-09-04
Authors: Jingchen Shao; Susann Li; Lars Palmqvist; Linda Fogelstrand; Stella Y Wei; Kiran Busayavalasa; Kui Liu; Viktor M Liu Journal: Exp Hematol Oncol Date: 2016-06-30